GlycoMimetics Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination With Venetoclax and Azacitidine
According to
At the 2020 annual meeting of the
About Uproleselan
Discovered and developed by
About
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include those relating to the planned or potential clinical development, and the potential benefits and impact, of the Company’s product candidate, uproleselan. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005428/en/
Investor Contact:
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact:
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
Source: